193965-35-4

Basic information

• Product Name: 7-METHOXYBENZO[B]THIOPHENE-2-BORONIC ACID
• Synonyms: 7-METHOXYBENZO[B]THIOPHENE-2-BORONIC ACID;(7-Methoxybenzo[b]thiophen-2-yl)boronic acid
• CAS NO: 193965-35-4
• Molecular Formula: C9H9BO3S
• Molecular Weight: 208.04
• Mol File: 193965-35-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 423.1±48.0 °C(Predicted)
• Appearance: /
• Density: 1.35±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 6.85±0.30(Predicted)
• CAS DataBase Reference: 7-METHOXYBENZO[B]THIOPHENE-2-BORONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 7-METHOXYBENZO[B]THIOPHENE-2-BORONIC ACID(193965-35-4)
• EPA Substance Registry System: 7-METHOXYBENZO[B]THIOPHENE-2-BORONIC ACID(193965-35-4)

Safety Data

• Hazardous Substances Data: 193965-35-4(Hazardous Substances Data)

Usage

General Description

7-Methoxybenzo[B]Thiophene-2-Boronic Acid is a chemical compound that belongs to the class of boronic acids and contains a benzothiophene ring with a boronic acid functional group attached at the 2-position. It is commonly used as a building block in organic synthesis, particularly in the field of medicinal chemistry for the development of pharmaceuticals and agrochemicals. 7-Methoxybenzo[B]Thiophene-2-Boronic Acid has been reported to exhibit potential biological activities and has been used as a key intermediate in the synthesis of various biologically active molecules. Its unique structure and reactivity make it a valuable tool for the construction of complex organic compounds.

Upstream product

• 51830-50-3 1,1-diethoxy-2-(4-methylphenylthio)ethane 
• 88791-08-6 7-methoxybenzothiophene 
• 5419-55-6 Triisopropyl borate 

Relevant articles and documents

Compound with AMPK agonistic activity and preparation and application of prodrug thereof

The invention relates to a compound with AMPK agonistic activity and a prodrug thereof, and as well as a preparation method and medical application of a prodrug thereof. The compound has the structure shown in the formula (I), and the prodrug of the compound has the structure shown in the formula (II), wherein each group and the substituent are as defined in the specification. The invention discloses a preparation method of the compound and application of the compound in prevention and treatment AMPK related diseases, and the AMPK related diseases include, but are not limited to, energy metabolism abnormality related diseases. Neurodegenerative diseases and inflammation-related diseases and the like.

Antithrombotic diamines

This application relates to the use as thrombin inhibitors, coagulation inhibitors and thromboembolic disorder agents of diamines of formula I as defined herein. It also provides novel compounds of formula I, processes and intermediates for their preparation, and pharmaceutical formulations comprising the novel compounds of formula I.